Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Alnylam presents topline data from ILLUMINATE-A phase III study of lumasiran

Dec. 18, 2019

FDA removes partial clinical hold for multiple-ascending-dose study of RGLS-4326

Dec. 17, 2019

Aurinia reports data from pivotal study of voclosporin in lupus nephritis

Dec. 5, 2019

New macrophage metalloelastase inhibitors discovered at Foresee Pharmaceuticals

Dec. 4, 2019

AstraZeneca identifies new TRPC3 and TRPC6 antagonists

Nov. 28, 2019

Peroxiredoxin-1 as a novel therapeutic target in LPS-induced AKI

Nov. 28, 2019

Muscarinic acetylcholine M3 receptor positive allosteric modulators patented by Nippon Shinyaku

Nov. 27, 2019

Phase III ADVOCATE trial of avacopan in ANCA vasculitis meets primary endpoints

Nov. 26, 2019

CLCA1-TMEM16A-chloride current pathway mediates renal injury in aging and diabetes

Nov. 25, 2019

Klotho shows potential as therapeutic target in podocyte injury of diabetic nephropathy

Nov. 25, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.